2013
TIG1 Promotes the Development and Progression of Inflammatory Breast Cancer through Activation of Axl Kinase
Wang X, Saso H, Iwamoto T, Xia W, Gong Y, Pusztai L, Woodward WA, Reuben JM, Warner SL, Bearss DJ, Hortobagyi GN, Hung MC, Ueno NT. TIG1 Promotes the Development and Progression of Inflammatory Breast Cancer through Activation of Axl Kinase. Cancer Research 2013, 73: 6516-6525. PMID: 24014597, PMCID: PMC6135947, DOI: 10.1158/0008-5472.can-13-0967.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsApoptosisAxl Receptor Tyrosine KinaseBlotting, WesternCell AdhesionCell CycleCell MovementCell ProliferationDisease ProgressionFemaleFluorescent Antibody TechniqueHumansImmunoprecipitationInflammatory Breast NeoplasmsMediator ComplexMiceNeoplasm InvasivenessProto-Oncogene ProteinsReal-Time Polymerase Chain ReactionReceptor Protein-Tyrosine KinasesReverse Transcriptase Polymerase Chain ReactionRNA, MessengerRNA, Small InterferingSignal TransductionTumor Cells, CulturedConceptsInflammatory breast cancerBreast cancerAxl expressionMalignant propertiesHigh tumoral expressionIBC cell proliferationMatrix metalloproteinase-9Inhibited tumor growthIBC specimensIBC cellsShorter survivalTumoral expressionProteasome-dependent degradationMetalloproteinase-9TIG1 expressionNF-κBTherapeutic targetTumor growthReceptor tyrosine kinasesAxl functionLethal formAxlIBC treatmentCancerAggressive properties
2008
Research Issues Affecting Preoperative Systemic Therapy for Operable Breast Cancer
Wolff AC, Berry D, Carey LA, Colleoni M, Dowsett M, Ellis M, Garber JE, Mankoff D, Paik S, Pusztai L, Smith ML, Zujewski J. Research Issues Affecting Preoperative Systemic Therapy for Operable Breast Cancer. Journal Of Clinical Oncology 2008, 26: 806-813. PMID: 18258990, DOI: 10.1200/jco.2007.15.2983.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsAntineoplastic AgentsApoptosisBiomarkersBiomedical ResearchBreast NeoplasmsCell ProliferationEpidemiologic Research DesignErbB ReceptorsEthics, ClinicalFemaleGene Expression ProfilingHumansMastectomy, SegmentalNeoadjuvant TherapyPatient AdvocacyPreoperative CarePrognosisReceptors, SteroidTreatment OutcomeConceptsPreoperative systemic therapyOperable breast cancerSystemic therapyBreast cancerTrial designEnd pointCohesive multidisciplinary teamBreast conservation ratesEffective alternative therapyTrial end pointsLong-term outcomesSpecific breast cancer subtypesPredictors of responseNovel trial designsIntermediate end pointsBreast cancer subtypesIndividual patient subgroupsAdjuvant trialsPatient subgroupsSmall trialsAlternative therapiesMAIN OUTCOMEClinical careCancer subtypesMultidisciplinary team
2003
Chemotherapy-Induced Apoptosis and Bcl-2 Levels Correlate with Breast Cancer Response to Chemotherapy
Buchholz TA, Davis DW, McConkey DJ, Symmans WF, Valero V, Jhingran A, Tucker SL, Pusztai L, Cristofanilli M, Esteva FJ, Hortobagyi GN, Sahin AA. Chemotherapy-Induced Apoptosis and Bcl-2 Levels Correlate with Breast Cancer Response to Chemotherapy. The Cancer Journal 2003, 9: 33-41. PMID: 12602766, DOI: 10.1097/00130404-200301000-00007.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsApoptosisBiomarkers, TumorBiopsyBreast NeoplasmsDocetaxelDoxorubicinFemaleHumansIn Situ Nick-End LabelingMiddle AgedNeoplasm, ResidualPaclitaxelPredictive Value of TestsProspective StudiesProto-Oncogene Proteins c-bcl-2TaxoidsTime FactorsConceptsBreast cancer responsePathological complete responseCancer responseComplete responseResidual diseaseBcl-2Breast cancer primary tumorsApoptosis levelsBreast cancer treatmentBcl-2 expressionChemotherapy-induced apoptosisTreatment-induced apoptosisMann-Whitney testTumor cell apoptosisPrimary tumorCore biopsyPredictive markerDoxorubicin chemotherapySerial measurementsImmunohistochemical assaysChemotherapyPretreatment samplesLevel correlatesTumorsSemiquantitative immunohistochemical assay
1999
Chemo-signal therapy, an emerging new approach to modify drug resistance in breast cancer
Pusztai L, Esteva F, Cristofanilli M, Hung M, Hortobagyi G. Chemo-signal therapy, an emerging new approach to modify drug resistance in breast cancer. Cancer Treatment Reviews 1999, 25: 271-277. PMID: 10544071, DOI: 10.1053/ctrv.1999.0132.Peer-Reviewed Original ResearchConceptsBreast cancerResponse modifiersPromising new treatment modalityNew treatment modalitiesCombination of chemotherapyNon-cytotoxic agentsCurrent clinical researchClinical drug developmentTreatment modalitiesClinical trialsClinical experienceChemotherapyCytotoxic drugsDrug resistanceClinical researchCancerOncogene expressionGrowth factor signalingDrug developmentSelect groupTherapyDevelopment of novelEarly phaseDrugsFactor signaling
1998
Physiologic and Pathologic Drug Resistance in Ovarian Carcinoma: A Hypothesis Based on a Clonal Progression Model
Pusztai L, Siddik Z, Mills G, Bast R. Physiologic and Pathologic Drug Resistance in Ovarian Carcinoma: A Hypothesis Based on a Clonal Progression Model. Acta Oncologica 1998, 37: 629-640. PMID: 10050979, DOI: 10.1080/028418698429964.Peer-Reviewed Original ResearchConceptsEarly-stage ovarian cancerDrug-resistant cellsDrug resistanceDrug sensitivityOvarian cancerTumor progressionDisease-free survivalHigh-dose chemotherapyNumerous clinical studiesDifferent treatment strategiesCell populationsHigh response rateCorresponding normal tissuesInsufficient chemotherapyAdjuvant chemotherapyIntensive chemotherapyAdvanced diseaseClinical responseCombination chemotherapyConventional dosesMolecular biological observationsOvarian carcinomaPhysiological drug resistanceClinical failureClinical studies